<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Trellus Health Plc — News on 6ix</title>
<link>https://6ix.com/company/trellus-health-plc</link>
<description>Latest news and press releases for Trellus Health Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 13 Apr 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/trellus-health-plc" rel="self" type="application/rss+xml" />
<item>
<title>Pfizer Licensing Agreement Renewal</title>
<link>https://6ix.com/company/trellus-health-plc/news/pfizer-licensing-agreement-renewal</link>
<guid isPermaLink="true">https://6ix.com/company/trellus-health-plc/news/pfizer-licensing-agreement-renewal</guid>
<pubDate>Mon, 13 Apr 2026 06:00:00 GMT</pubDate>
<description>Trellus Health plc has renewed its Licensing Agreement with Pfizer Inc. to continue licensing patient support educational content for Pfizer's inflammatory bowel disease digital application. This renewal, following an initial agreement in Q2 2024, underscores user engagement and the value of Trellus Health's resilience-driven approach. The company has reduced its monthly cash burn to approximately $300k as of March 2026, and with this agreement and a loan, expects its cash runway to extend into </description>
</item>
<item>
<title>Funding Update</title>
<link>https://6ix.com/company/trellus-health-plc/news/funding-update-27</link>
<guid isPermaLink="true">https://6ix.com/company/trellus-health-plc/news/funding-update-27</guid>
<pubDate>Thu, 02 Apr 2026 06:00:00 GMT</pubDate>
<description>Trellus Health plc has secured a US$50,000 unsecured loan from CEO and Co-Founder Dr. Marla Dubinsky, bearing 5% annual interest and maturing in 12 months, which extends the company's cash runway into late April 2026. While a convertible facility remains available, its utilization is constrained by market conditions. The company's Independent Directors, in consultation with its Nominated Adviser, deem the terms of this related party transaction fair and reasonable for shareholders, as Trellus He</description>
</item>
<item>
<title>MSA Signed and Funding Update</title>
<link>https://6ix.com/company/trellus-health-plc/news/msa-signed-and-funding-update</link>
<guid isPermaLink="true">https://6ix.com/company/trellus-health-plc/news/msa-signed-and-funding-update</guid>
<pubDate>Fri, 27 Mar 2026 07:00:00 GMT</pubDate>
<description>Trellus Health plc has signed a master services agreement with Gastro Health, a US clinical site network, to leverage its TrialSet™ suite of engagement tools and co-market services, which is expected to create future commercial opportunities. The company has also reduced its monthly cash burn to approximately $300,000 as of March 2026, extending its cash runway into early April 2026, and is in discussions for a potential loan from directors and exploring other funding options to further extend i</description>
</item>
<item>
<title>Issue of Equity - Conversion of Loan Notes</title>
<link>https://6ix.com/company/trellus-health-plc/news/issue-of-equity-conversion-of-loan-notes</link>
<guid isPermaLink="true">https://6ix.com/company/trellus-health-plc/news/issue-of-equity-conversion-of-loan-notes</guid>
<pubDate>Tue, 10 Mar 2026 07:00:00 GMT</pubDate>
<description>Trellus Health PLC has issued 16,438,845 new Ordinary Shares following the conversion of £50,000 of principal from its Secured Convertible Loan Notes, with admission to AIM expected around March 13, 2026. This issuance represents 0.2% of the Company's issued share capital, and following this, the total number of voting rights will be 241,612,340.
Disclaimer*</description>
</item>
<item>
<title>Contract Extension with Johnson & Johnson</title>
<link>https://6ix.com/company/trellus-health-plc/news/contract-extension-with-johnson-and-johnson</link>
<guid isPermaLink="true">https://6ix.com/company/trellus-health-plc/news/contract-extension-with-johnson-and-johnson</guid>
<pubDate>Wed, 18 Feb 2026 07:05:00 GMT</pubDate>
<description>Trellus Health plc has secured a six-month contract extension with Johnson & Johnson Health Care Systems for its Trellus Elevate platform, supporting patients with inflammatory bowel disease, with the same economic terms including a fixed monthly management fee. This extension, effective until mid-2026, was driven by strong engagement and satisfaction metrics achieved during the initial pilot phase, leading J&J to broaden patient access channels. The company also continues to deploy its TrialSet</description>
</item>
<item>
<title>Issue of Equity</title>
<link>https://6ix.com/company/trellus-health-plc/news/issue-of-equity-122</link>
<guid isPermaLink="true">https://6ix.com/company/trellus-health-plc/news/issue-of-equity-122</guid>
<pubDate>Wed, 11 Feb 2026 07:00:00 GMT</pubDate>
<description>Trellus Health plc has issued 5,538,461 new Ordinary Shares following the conversion of £27,000 of outstanding Secured Convertible Loan Notes, with admission to trading on AIM expected around 12 February 2026. Post-admission, the Company will have 186,277,563 Ordinary Shares in issue, representing the total number of voting rights.
Disclaimer*</description>
</item>
<item>
<title>Holding(s) in Company</title>
<link>https://6ix.com/company/trellus-health-plc/news/holdings-in-company-446</link>
<guid isPermaLink="true">https://6ix.com/company/trellus-health-plc/news/holdings-in-company-446</guid>
<pubDate>Fri, 06 Feb 2026 10:45:00 GMT</pubDate>
<description>Icahn School of Medicine at Mount Sinai has notified Trellus Health plc of a change in its major holding, with its voting rights decreasing from 25% to 22.3%, representing 40,384,897 voting rights. This change is not due to a disposal of shares but rather an increase in the total issued share capital following new ordinary shares issued to Alumni Capital. Mount Sinai Health System, Inc., as the sole member of Icahn School of Medicine at Mount Sinai, may also be deemed to beneficially own these s</description>
</item>
<item>
<title>Business update</title>
<link>https://6ix.com/company/trellus-health-plc/news/business-update-28</link>
<guid isPermaLink="true">https://6ix.com/company/trellus-health-plc/news/business-update-28</guid>
<pubDate>Tue, 03 Feb 2026 07:00:00 GMT</pubDate>
<description>Trellus Health plc reported progress in its clinical trials and pharmaceutical verticals, securing a 12-month contract with ICON plc for Takeda-sponsored trials and a similar contract with PSI Inc. for Sanofi-sponsored trials, alongside ongoing support for an AstraZeneca Phase 2 trial. The company also advanced its collaboration with Johnson & Johnson and renewed its agreement with Pfizer, while expecting revenue of approximately $545,000 for the year ended 2025 and reducing its monthly cash bur</description>
</item>
<item>
<title>Grant of Share Options</title>
<link>https://6ix.com/company/trellus-health-plc/news/grant-of-share-options-40</link>
<guid isPermaLink="true">https://6ix.com/company/trellus-health-plc/news/grant-of-share-options-40</guid>
<pubDate>Thu, 29 Jan 2026 07:00:00 GMT</pubDate>
<description>Trellus Health plc has issued 19,230,769 new Ordinary Shares in lieu of cash settlement for Secured Convertible Loan Notes, with admission to trading on AIM expected around February 2, 2026. Following this, the company will have a total of 180,739,102 Ordinary Shares in issue, each carrying one vote, and no shares held in treasury. This issuance is a result of resolutions passed at a General Meeting on January 20, 2026, following a prior announcement on December 30, 2025.
Disclai</description>
</item>
<item>
<title>Result of Meeting</title>
<link>https://6ix.com/company/trellus-health-plc/news/result-of-meeting-29</link>
<guid isPermaLink="true">https://6ix.com/company/trellus-health-plc/news/result-of-meeting-29</guid>
<pubDate>Tue, 20 Jan 2026 14:00:00 GMT</pubDate>
<description>Trellus Health PLC announced that all resolutions presented at its General Meeting on January 20, 2026, were passed with overwhelming support, with votes in favour ranging from 99.87% to 99.90%. This indicates strong shareholder confidence in the company's proposed actions, which are crucial for its ongoing operations and strategic direction.
Disclaimer*</description>
</item>
<item>
<title>Proposed issue of Secured Convertible Loan Notes</title>
<link>https://6ix.com/company/trellus-health-plc/news/proposed-issue-of-secured-convertible-loan-notes</link>
<guid isPermaLink="true">https://6ix.com/company/trellus-health-plc/news/proposed-issue-of-secured-convertible-loan-notes</guid>
<pubDate>Tue, 30 Dec 2025 17:00:00 GMT</pubDate>
<description>Trellus Health plc announced a proposed issue of up to £5 million in Secured Convertible Loan Notes to an institutional investor to extend its cash runway, subject to shareholder approval. The facility, available in multiple tranches over 12 months, includes conversion at a discount to market price and associated warrants. The net proceeds from the first two tranches, totaling £737,500, are expected to sustain the company until late Q1 2026, with further tranches dependent on conditions being me</description>
</item>
<item>
<title>Finance update</title>
<link>https://6ix.com/company/trellus-health-plc/news/finance-update</link>
<guid isPermaLink="true">https://6ix.com/company/trellus-health-plc/news/finance-update</guid>
<pubDate>Mon, 24 Nov 2025 07:00:00 GMT</pubDate>
<description>Trellus Health plc has secured a US$600,000 unsecured loan from its substantial shareholder, the Icahn School of Medicine at Mount Sinai, which will extend the company's cash runway to late January 2026 and support its commercial strategy. The loan is non-interest bearing for the first six months, after which it accrues 8% annual interest, payable in cash or new ordinary shares at a conversion price of 0.525 pence, with a cap preventing Mount Sinai from exceeding 29.9% of the company's issued sh</description>
</item>
<item>
<title>Contract signed with second leading CRO</title>
<link>https://6ix.com/company/trellus-health-plc/news/contract-signed-with-second-leading-cro</link>
<guid isPermaLink="true">https://6ix.com/company/trellus-health-plc/news/contract-signed-with-second-leading-cro</guid>
<pubDate>Fri, 07 Nov 2025 07:00:00 GMT</pubDate>
<description>Trellus Health plc (AIM: TRLS) announced a 12-month contract with a second major global clinical research organisation to deploy its Trellus TrialSet™ offering, commencing before year-end. This agreement, structured with an upfront fee, monthly management fee, and milestone payments, will support recruitment and enrolment optimisation for two late-stage immunology and inflammation clinical trials. While this marks a strategic growth area and validates their offering, the company explicitly state</description>
</item>
<item>
<title>Contract Signed with Leading Global CRO</title>
<link>https://6ix.com/company/trellus-health-plc/news/contract-signed-with-leading-global-cro</link>
<guid isPermaLink="true">https://6ix.com/company/trellus-health-plc/news/contract-signed-with-leading-global-cro</guid>
<pubDate>Wed, 22 Oct 2025 06:00:00 GMT</pubDate>
<description>Trellus Health PLC has signed a 12-month contract with a major global Clinical Research Organisation (CRO) to enhance recruitment and enrolment for an immunology and inflammation clinical trial, commencing later this year. The contract includes an upfront fee, monthly management fees, and milestone payments tied to key performance indicators, such as the number of participants opting into the Trellus TrialSet™ program, increases in qualified participant referrals, and reductions in screen failur</description>
</item>
<item>
<title>Company Update</title>
<link>https://6ix.com/company/trellus-health-plc/news/company-update-32</link>
<guid isPermaLink="true">https://6ix.com/company/trellus-health-plc/news/company-update-32</guid>
<pubDate>Tue, 21 Oct 2025 06:00:00 GMT</pubDate>
<description>Trellus Health plc announced that cost-saving measures have extended their cash runway to early December 2025, beyond the previously announced early November timeline. The company anticipates reducing its average monthly cash burn from approximately $440,000 to around $395,000. Contract negotiations are in late stages for one collaboration with a leading global CRO to support a mid-stage clinical trial. Negotiations are progressing on a separate collaboration with a second leading global CRO fol</description>
</item>
<item>
<title>Interim results - Replacement</title>
<link>https://6ix.com/company/trellus-health-plc/news/interim-results-replacement-14</link>
<guid isPermaLink="true">https://6ix.com/company/trellus-health-plc/news/interim-results-replacement-14</guid>
<pubDate>Mon, 08 Sep 2025 14:15:00 GMT</pubDate>
<description>Trellus Health PLC announced its unaudited interim results for the six months ended June 30, 2025. The company's revenue year-to-date is $379k, a significant increase from $50k in the same period last year. The adjusted EBITDA loss was $2.6m, an improvement compared to a $3.6m loss in the prior year. Trellus Health's net cash stood at $1.6m as of June 30, 2025, down from $4.3m at the end of 2024, providing a cash runway into early November 2025. The average monthly burn has further decreased by </description>
</item>
<item>
<title>Interim results</title>
<link>https://6ix.com/company/trellus-health-plc/news/interim-results-225</link>
<guid isPermaLink="true">https://6ix.com/company/trellus-health-plc/news/interim-results-225</guid>
<pubDate>Mon, 08 Sep 2025 06:00:00 GMT</pubDate>
<description>Trellus Health PLC announced its unaudited interim results for the six months ended June 30, 2025, revealing a net cash position of $1.6 million, down from $4.3 million at the end of 2024, with the cash runway extending into early November 2025. The average monthly burn rate has decreased by approximately 10% to $440k per month since August 1, 2025. The adjusted EBITDA loss was $3.5 million, consistent with management's expectations, compared to a $3.6 million loss in the same period last year. </description>
</item>
<item>
<title>Notice of Results</title>
<link>https://6ix.com/company/trellus-health-plc/news/notice-of-results-142</link>
<guid isPermaLink="true">https://6ix.com/company/trellus-health-plc/news/notice-of-results-142</guid>
<pubDate>Wed, 03 Sep 2025 06:00:00 GMT</pubDate>
<description>Trellus Health plc will release its interim results for the period ending June 30, 2025, on Monday, September 8, 2025. The healthcare company, known for its Trellus Elevate digital platform, integrates data analytics with resilience programs to manage chronic conditions. Trellus Elevate has demonstrated significant results, including over 90% fewer hospitalizations and a reduction of over 70% in emergency room visits among Inflammatory Bowel Disease (IBD) patients.
Disclaimer*</description>
</item>
<item>
<title>Result of AGM</title>
<link>https://6ix.com/company/trellus-health-plc/news/result-of-agm-392</link>
<guid isPermaLink="true">https://6ix.com/company/trellus-health-plc/news/result-of-agm-392</guid>
<pubDate>Tue, 01 Jul 2025 06:00:00 GMT</pubDate>
<description>Result of AGM.</description>
</item>
<item>
<title>AGM Statement</title>
<link>https://6ix.com/company/trellus-health-plc/news/agm-statement-123</link>
<guid isPermaLink="true">https://6ix.com/company/trellus-health-plc/news/agm-statement-123</guid>
<pubDate>Mon, 30 Jun 2025 06:00:00 GMT</pubDate>
<description>AGM Statement.</description>
</item>
</channel>
</rss>